Neovest fine stokes the EMS transaction fee debate

EMS transaction fees PoV main pic

The SEC’s fine for J.P. Morgan’s Neovest could signal a shift in how the industry views contentious EMS transaction fees. Chartis’ research shows that, as regulatory pressure mounts, investment managers and vendors may have to rethink their transaction-fee strategies.

EMS transaction fees: benefit or bane?

On 28 June the Securities and Exchange Commission (SEC) announced that it had levied a fine on Neovest, a division of JPMorgan Chase, for operating as an unregistered broker-dealer

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risktech Forum? Register for access

If you already have an account, please sign in here.

To continue reading...

You need to sign in to use this feature. If you don’t have a RiskTech Forum account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: